Hilary Hoey

Hilary Hoey

Auto-generated profile, based on publicly available information

Hilary Hoey

Department of Pediatrics, CHI at Tallaght University Hospital, Trinity College Dublin, The University of Dublin , Dublin 24 , Ireland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2016 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
EREdna F. Roche
Edna F. Roche
AMAmanda M. McKenna
Amanda M. McKenna
KRKerry J Ryder
Kerry J Ryder
ABAdrienne A. Brennan
Adrienne A. Brennan
MOMyra O’regan
Myra O’regan
HHHilary Mcv Hoey
Hilary Mcv Hoey

1 October 2014 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
RJRikke Beck Jensen
Rikke Beck Jensen
ATAjay Thankamony
Ajay Thankamony
SOSusan M O'COnnell
Susan M O'COnnell
JKJeremy Kirk
Jeremy Kirk
MDMalcolm Donaldson
Malcolm Donaldson
AJAnders Juul
Anders Juul
Background: Short children born small for gestational age (SGA) are treated with a GH dose based on body size, but treatment may lead to high levels of IGF1. The objective was to evaluate IGF1 titration of GH dose in contrast to current dosing strategies.Methods: In the North European Small-for-Gestational-Age Study (NESGAS), 92 short pre-pubertal children born SGA were randomised after 1 year of high-dose GH treatment (67 μg/kg per day) to three different regimens: high dose (67 μg/kg per day), low dose (35 μg/kg per day) or IGF1 titration.Results: The average dose during the second year of the randomised trial did not differ between the IGF1 titration group (38 μg/kg per day,s.d.0.019) and the low-dose group (35 μg/kg per day,s.d.0.002;P=0.46), but there was a wide variation in the IGF1 titration group (range 10–80 μg/kg per day). The IGF1 titration group had significantly lower height gain (0.17 SDS,s.d.0.18) during the second year of the randomised trial compared with the high-dose group (0.46 SDS,s.d.0.25), but not significantly lower than the low-dose group (0.23 SDS,s.d.0.15;P=0.17). The IGF1 titration group had lower IGF1 levels after 2 years of the trial (mean 1.16,s.d.1.24) compared with both the low-dose (mean 1.76,s.d.1.48) and the high-dose (mean 2.97,s.d.1.63) groups.Conclusion: IGF1 titration of GH dose in SGA children proved less effective than current dosing strategies. IGF1 titration resulted in physiological IGF1 levels with a wide range of GH dose and a poorer growth response, which indicates the role of IGF1 resistance and highlights the heterogeneity of short SGA children.

25 August 2023 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
APAman Bhakti Pulungan
Aman Bhakti Pulungan
HPHelena Arnetta Puteri
Helena Arnetta Puteri
ARAmajida F Ratnasari
Amajida F Ratnasari
HHHilary Hoey
Hilary Hoey
Agustini UtariAgustini Utari
Agustini Utari
MFMychelle Farmer
Mychelle Farmer
The rising epidemic of childhood obesity worldwide is a major public health challenge. Despite its urgency, there is a lack of data on the awareness and implementation of preventative measures. This study aims to identify areas for improvement in the prevention and management of childhood obesity worldwide. A cross-sectional electronic survey was distributed to 132 national pediatric societies members of the International Pediatric Association. Twenty-eight participants from different countries across six WHO regions completed the survey. Most participants reported that national prevalence data of childhood obesity is available (78.6%), and the number increased during the COVID-19 pandemic (60.7%). In most countries (78.6%), the amount of sugar and salt is provided in children's products, but only 42.9% enacted regulations on children-targeted advertising. Childhood obesity prevention programs from the government (64.3%) and schools (53.6%) are available with existing support from private or non-profit organizations (71.4%). Participants were aware of WHO's guidance concerning childhood obesity (78.6%), while fewer were aware of UNICEF's guidance (50%). Participants reported that WHO/UNICEF guidance acted as a reference to develop policies, regulations and national programs. However, progress is hindered by poor compliance. Lastly, participants provided suggestions on tackling obesity with responses ranging from developing and reinforcing policies, involvement of schools, and prevention across all life stages. There are different practices in implementing prevention measures against childhood obesity globally, particularly in statutory regulation on food advertising and national programs. While support and awareness is relatively high, its implementation is hindered. This reflects the need for prompt country-specific evaluation and interventions.

11 April 2011 in Pediatric Diabetes
Verified
Journal Article
Open access
PDF file
RHRagnar Hanas
Ragnar Hanas
CBCarine de Beaufort
Carine de Beaufort
HHHilary Hoey
Hilary Hoey
BABarbara Anderson
Barbara Anderson
Hanas R, de Beaufort C, Hoey H, Anderson B. Insulin delivery by injection in children and adolescents with diabetes. Type 1 diabetes is treated with insulin, which has traditionally been delivered by vial and syringe. However, for many patients, dosing inaccuracy, pain, anxiety, inconvenience, and social acceptability present barriers to this method of administration 1-5 . This has contributed to the increased popularity of alternative insulin delivery systems, including pen delivery devices 4, 6 . Evidence suggests that discreet devices, such as insulin pens, facilitate adherence to intensive insulin therapy regimens, help improve lifestyle flexibility, and reduce injection pain compared with the conventional syringe‐based regimens, as shown in studies in adults and adolescents 7 . In addition, compared with the vial and syringe method of insulin administration, pens may provide more accurate dosing – which is particularly important in children – thereby improving short‐term blood glucose control and potentially improving long‐term outcomes 5, 8 . Children, in particular, may benefit from insulin pens that are simple to use as adherence issues may be more evident in this patient group 9 . Pens for insulin delivery in children with type 1 diabetes have been used for a long time in Europe, and have recently gained in popularity in many other places around the world 4, 10 . Furthermore, the conventional vial and syringe method of insulin delivery is beginning to be considered as obsolete 11 . Moreover, there is a continued drive to improve insulin pen technology, to refine and enhance the functionality and usability of these pens. However, despite recent advances in pen design and function, the selection of pens available especially for children is limited.

20 November 2017 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
TSTimothy Skinner
Timothy Skinner
KLKarin S Lange
Karin S Lange
HHHilary Hoey
Hilary Hoey
HMHenrik B Mortensen
Henrik B Mortensen
HAHenk‐Jan Aanstoot
Henk‐Jan Aanstoot
TGThe Hvidoere Study Group
The Hvidoere Study Group

29 October 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
MWMathilde Gersel Wegmann
Mathilde Gersel Wegmann
RJRikke Beck Jensen
Rikke Beck Jensen
ATAjay Thankamony
Ajay Thankamony
JFJan Frystyk
Jan Frystyk
EREdna Roche
Edna Roche
AJAnders Juul
Anders Juul
Background: Some children born small for gestational age (SGA) experience supra-physiological insulin-like growth factor-I (IGF-I) concentrations during GH treatment. However, measurements of total IGF-I concentrations may not reflect the bioactive fraction of IGF-I which reaches the IGF-I receptor at target organs. We examined endogenous IGF-bioactivity using an IGF-I kinase receptor activation (KIRA) assay that measures the ability of IGF-I to activate the IGF-IR in vitro. Aim: To compare responses of bioactive IGF and total IGF-I concentrations in short GH treated SGA children in the North European Small for Gestational Age Study (NESGAS). Material and method: In NESGAS, short SGA children (n = 101, 61 males) received GH at 67 µg/kg/day for 1 year. IGF-I concentrations were measured by Immulite immunoassay and bioactive IGF by in-house KIRA assay. Results: Bioactive IGF increased with age in healthy pre-pubertal children (n = 94). SGA children had low-normal bioactive IGF levels at baseline (-0.12 (1.8 SD), increasing significantly after one year of high-dose GH treatment to 1.1 (1.4) SD, P < 0.01. Following high-dose GH, 68% (n = 65) of SGA children had a total IGF-I concentration >2SD (mean IGF-I 2.8 SDS), whereas only 15% (n = 15) had levels of bioactive IGF slightly above normal reference values. At baseline, bioactive IGF (SDS) was significantly correlated to height (SDS) (r = 0.29, P = 0.005), in contrast to IGF-I (SDS) (r = 0.17, P = 0.10). IGF-I (SDS) was inversely correlated to delta height (SDS) after one year of high-dose GH treatment (r = -0.22, P = 0.02). Conclusion: In contrast to total IGF-I concentrations, bioactive IGF stayed within the normal reference ranges for most SGA children during the first year of GH treatment.